Communiqués Zelluna ASA

Actions

ZLNA

NO0013524942

Recherche biotechnologique et médicale

Cours en clôture Oslo Bors 12/10/2026			Varia. 5j.	Varia. 1 janv.
19,00 ^NOK	-3,31%		-2,31%	+37,68%

20/08	Zelluna ASA publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
17/08	Zelluna ASA reçoit la recommandation du Comité indépendant de surveillance des données de poursuivre le recrutement des patients pour l'étude ZIMA-101	CI

Communiqués

08:00	Zelluna ASA: Invitation to Third Quarter 2026 Results Webcast Including ZIMA-101 Clinical Progress Update	GL
09/09	Zelluna ASA – Extraordinary General Meeting held on September 9, 2026	GL
20/08	Zelluna ASA: Second Quarter 2026 results	GL
17/08	Zelluna receives Independent Data Monitoring Committee recommendation to continue patient enrolment in ZIMA-101	GL
17/08	Zelluna ASA: Notice of EGM – experienced international biotech executive proposed for election to the Board and Board member steps down	GL
13/08	Zelluna ASA: Invitation to Second Quarter 2026 Results Webcast Presentation	GL
10/08	Zelluna ASA: New share capital registered	GL
06/08	Zelluna ASA: Disclosure of large shareholding	GL
04/08	Zelluna ASA: Disclosure of large shareholding	GL
04/08	Zelluna ASA: Issuance of shares to Inven2 through set-off of settlement amounts under option and license agreement	GL
13/07	Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial	GL
13/07	Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial	AQ
02/07	Zelluna ASA - Grant of Share Options	GL
30/06	Zelluna ASA awarded NOK 16 million Research Council of Norway grant	GL
29/06	Zelluna ASA: Mandatory notification of trade – Return of lent shares following Private Placement	GL
29/06	Zelluna ASA: New share capital registered	GL
29/06	Zelluna ASA activates The Royal Marsden as second clinical site for ZIMA-101, expanding clinical execution capabilities	GL
26/06	Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided	GL
18/06	Zelluna ASA: Disclosure of large shareholding	GL
18/06	Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement	GL
18/06	Zelluna ASA – Mandatory notification of trade – Subscription and share lending in Private Placement	AQ
18/06	Zelluna ASA: Private Placement and Retail Offering successfully placed	GL
17/06	Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data	GL
07/05	Zelluna ASA: First Quarter 2026 results	GL
07/05	Zelluna ASA: First Quarter 2026 results	AQ